Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Operations (2024 - 2025)

Historic Cash from Operations for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$17.5 million.

  • Xilio Therapeutics' Cash from Operations fell 2796.23% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.2 million, marking a year-over-year change of. This contributed to the annual value of -$18.4 million for FY2024, which is 7321.77% up from last year.
  • As of Q3 2025, Xilio Therapeutics' Cash from Operations stood at -$17.5 million, which was down 2796.23% from -$14.5 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Cash from Operations ranged from a high of $29.0 million in Q1 2025 and a low of -$17.5 million during Q3 2025